Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;187(2):203-210.
doi: 10.1111/bjd.21236. Epub 2022 May 22.

Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials

Affiliations

Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials

Amit Garg et al. Br J Dermatol. 2022 Aug.

Abstract

Background: Few validated instruments exist for use in hidradenitis suppurativa (HS) trials.

Objectives: To develop a novel HS Investigator Global Assessment (HS-IGA) and to validate its psychometric properties.

Methods: Development of HS-IGA involved discussion among stakeholders, including patients, within HISTORIC. Data from replicate phase III randomized controlled trials evaluating HS treatment were utilized. Multivariate models identified lesion type and body region as variables of importance. Classification and regression trees for ordinal responses were built. Validation included assessment of test-retest reliability, predictive validity, responsiveness and clinical meaningfulness.

Results: There were 3024 unique measurements available in PIONEER I. Mean and median lesion counts by region were largely <10 and were highest in axillary and inguinal regions. The mean and median number of regions involved were ≤ 3 for individual lesions and combinations. Regardless of lesion type, axillary and inguinal regions most influenced the HS-IGA score. Accordingly, regions were combined into a six-point IGA based on the maximum lesion number in either upper or lower body regions with a score of 0 (0-1 lesions), 1 (2-5), 2 (6-10), 3 (11-15), 4 (16-20) and 5 (≥ 20 lesions). The intraclass correlation coefficient for test-retest reliability was 0·91 (95% confidence interval 0·87-0·94). Spearman's rank order correlations (SROCs) with HS-PGA and Hidradenitis Suppurativa Clinical Response (HiSCR) were 0·73 and 0·51, respectively (P < 0·001 for both comparisons). SROCs with Dermatology Life Quality Index (DLQI), pain numerical rating scale and HS-QoL were 0·42, 0·34 and -0·25, respectively (P < 0·001 for all comparisons). HS-IGA was responsive at weeks 12 and 36. Predictive convergent validity was very good with HS-PGA (area under the curve = 0·89) and with HiSCR (area under the curve = 0·82). Predictive divergent validity was low with DLQI and HS-QoL.

Conclusions: HS-IGA has moderate-to-strong psychometric properties and is simple to calculate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anatomical regions and region combinations explored in development of the Hidradenitis Suppurativa Investigator Global Assessment. L, left; R, right. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 2
Figure 2
Type of lesion and region drivers of Hidradenitis Suppurativa Physician Global Assessment (HS‐PGA). Multivariate regression models using the PIONEER I development dataset showing which lesion types and region combinations most influence HS‐PGA, with consistent results using both (a) error rate and (b) ranked probability score. [Colour figure can be viewed at wileyonlinelibrary.com]

Similar articles

Cited by

References

    1. Garg A, Kirby JS, Lavian J et al. Sex‐ and age‐adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol 2017; 153:760–4. - PMC - PubMed
    1. Garg A, Lavian J, Lin G et al. Incidence of hidradenitis suppurativa in the United States: a sex‐ and age‐adjusted population analysis. J Am Acad Dermatol 2017; 77:118–22. - PubMed
    1. Garg A, Neuren E, Cha D et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) project. J Am Acad Dermatol 2020; 82:366–76. - PubMed
    1. Reddy S, Strunk A, Garg A. Comparative overall comorbidity burden among patients with hidradenitis suppurativa. JAMA Dermatol 2019; 155:797–802. - PMC - PubMed
    1. Reddy S, Strunk A, Garg A. All‐cause mortality among patients with hidradenitis suppurativa: a population‐based cohort study in the United States. J Am Acad Dermatol 2019; 81:937–42. - PubMed

MeSH terms

Substances